Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers

Research output: Contribution to journalArticlepeer-review


The criteria for the clinical diagnosis of AD include the analysis of biomarkers of the underlying brain disease pathology; a set of cerebrospinal fluid (CSF) tests, amyloid-β1-42 (Aβ42), total-tau (t-tau), and phosphorylated tau (p-tau), are available and their performance in a clinical setting has been assessed in several studies. Thus, in dementia research, great advances have been made in the discovery of putative biomarkers; however, disappointingly, few of them have been translated into clinically applicable assays. To find biomarkers able to reliably detect AD pathology already at prodromal stages and in blood is even more important. Recent technical breakthroughs have provided ultrasensitive methods that allow the detection of brain-specific proteins in blood. In the present review, we will focus on the usefulness of ultrasensitive technologies for biomarker discovery and trace elements detection; moreover, we will review studies on circulating nano-compartments, a promising novel source of material for molecular diagnostics.

Original languageEnglish
Pages (from-to)1507-1518
Number of pages12
JournalJournal of Alzheimer's disease : JAD
Issue number4
Publication statusPublished - 2018


Dive into the research topics of 'Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers'. Together they form a unique fingerprint.

Cite this